This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:tests:dexa [01.03.2019] – [Understanding the Scores] sallieq | home:tests:dexa [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 6: | Line 6: | ||
- | Dual Energy X-ray Absorptiometry (DEXA) is a common method of testing bone density as [[http:// | + | Dual Energy X-ray Absorptiometry (DEXA) is a common method of testing bone density as [[https:// |
===== Testing for osteoporosis ===== | ===== Testing for osteoporosis ===== | ||
Line 28: | Line 28: | ||
The reproducibility of DEXA scores is frequently reported at 1-2 percent. That 1-2 percent is the average, but the range of reproducibility can vary as much as 7 percent. Variations come from changes in machine reading (using the same machine), technologists who are doing the test, and slight changes and body positioning, | The reproducibility of DEXA scores is frequently reported at 1-2 percent. That 1-2 percent is the average, but the range of reproducibility can vary as much as 7 percent. Variations come from changes in machine reading (using the same machine), technologists who are doing the test, and slight changes and body positioning, | ||
- | A few more issues related to DEXA scores are covered in this Wikipedia article which says, inter alia, "It is important for patients to get repeat BMD measurements done on the same machine each time, or at least a machine from the same manufacturer. Error between machines, or trying to convert measurments from one manufacturer' | + | A few more issues related to DEXA scores are covered in a Wikipedia article which says, inter alia, "It is important for patients to get repeat BMD measurements done on the same machine each time, or at least a machine from the same manufacturer. Error between machines, or trying to convert measurments from one manufacturer' |
Line 50: | Line 50: | ||
A Review - Vitamin D and Calcium in Sarcoidosis (7-5-03) | A Review - Vitamin D and Calcium in Sarcoidosis (7-5-03) | ||
- | http:// | + | https:// |
| | ||
- | The Danish epidemiologist Brot studied 500 healthy women ( that is they were not drawn from a population with particular health issues) aged 42 to 58 and concluded that in this group bone density was strongly inversely proportional to 1,25 D levels ( that is low bone density was strongly associated with high 1,25 D levels) and only rather weakly directly proportional to 25 D levels. The sample was chosen randomly - and was not done to test the impact of any particular treatment programme. (({{pubmed> | + | The Danish epidemiologist Brot studied 500 healthy women ( that is they were not drawn from a population with particular health issues) aged 42 to 58 and concluded that in this group bone density was strongly inversely proportional to 1,25 D levels ( that is low bone density was strongly associated with high 1,25 D levels) and only rather weakly directly proportional to 25 D levels. The sample was chosen randomly - and was not done to test the impact of any particular treatment programme. (({{pmid> |
- | Influence of smoking (({{pubmed> | + | Influence of smoking (({{pmid> |
- | vitamin K(1) intake was not associated with effects on BMD or fracture risk. (({{pubmed> | + | vitamin K(1) intake was not associated with effects on BMD or fracture risk. (({{pmid> |
- | Dietary intake of folate, but not vitamin B2 or B12, is associated with increased bone mineral density 5 years after the menopause: results from a 10-year follow-up study in early postmenopausal women. | + | Dietary intake of folate, but not vitamin B2 or B12, is associated with increased bone mineral density 5 years after the menopause: results from a 10-year follow-up study in early postmenopausal women. |
| | ||
Line 68: | Line 68: | ||
When patients with an elevated level of 1,25-D are given Fosamax (or other biphosphanates), | When patients with an elevated level of 1,25-D are given Fosamax (or other biphosphanates), | ||
- | {{tag> | + | {{tag> |
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
TECH | TECH | ||
Line 151: | Line 152: | ||
by Gillian Sanson An interview with her here: | by Gillian Sanson An interview with her here: | ||
//BROKEN LINK// :- | //BROKEN LINK// :- | ||
- | [[http:// | + | [[https:// |
Although she does not have our new information on " | Although she does not have our new information on " | ||
Line 161: | Line 162: | ||
- | http:// | + | https:// |
< | < | ||
Line 171: | Line 172: | ||
- | * | + | * </ |